For most cancers, African-Americans have the highest mortality rates and shortest survival times of any racial or ethnic group in the US. Furthermore, compared with other racial/ethnic groups, African-Americans experience the highest rates of late-stage cancers and consequently the poorest cancer outcomes.\(^1\) In addition to later-stage cancer diagnoses, African-American cancer patients in the US frequently receive a different standard of care, even if diagnosed at the same stage of disease.\(^1,6\) Evidence further shows that when multiple treatment regimens are available, African-Americans are more likely to receive a less efficacious form of treatment, do not consistently receive information regarding all available treatment options, and are less likely to be referred to a specialist and/or to a chemoprevention clinical trial.\(^2,6\) Even though tremendous advances in cancer detection and treatment have benefited all populations, and despite targeted efforts aimed at addressing gaps in cancer outcomes in racial/ethnic minorities, African-Americans continue to suffer disproportionally from every major form of cancer (see Table 1).\(^1\)

The widespread racial disparity in the early detection of cancer and in cancer morbidity, mortality, treatment, and survival are well-documented and reflect a national phenomenon. These persistent racial/ethnic disparities, which are often magnified in the major cancers such as cancers of the lung, colon and rectum, breast, and prostate, have prompted federal agencies to develop national cancer control initiatives and programs to assist states in eliminating cancer disparities in communities of color.\(^7,8\) Recommendations and initiatives targeting racial/ethnic minority populations in general and African-Americans specifically have been outlined in numerous reports such as ‘Healthy People 2010’ (HP 2010),\(^9\) ‘The Unequal Burden of Cancer,’\(^10\) and the landmark document ‘Unequal Treatment: Confronting Racial and Ethnic Disparities in Healthcare.’\(^11\) These documents, along with a host of data from research studies and clinical trial reports, have repeatedly confirmed that the disparity between racial/ethnic minority populations and Caucasians in the US persists.

However, those who are committed to reducing (and eventually eliminating) healthcare disparities in general and cancer disparities specifically concede that the time has come to move beyond merely documenting racial/ethnic disparities and to begin to focus our efforts and resources on strategies to address the seemingly intractable racial/ethnic disparities among social groups. We know that addressing the cancer disparity in African-Americans and other racial/ethnic minority groups requires targeted, multidisciplinary efforts that span the cancer continuum. Indeed, a number of national initiatives and community-based programs and interventions specifically targeting African-Americans and other racial/ethnic minority populations are under way.\(^10–13\) However, to date reducing the racial/ethnic disparity among social groups has proved to be an elusive goal.

It is the complex meaning of race/ethnicity and the manner in which it is used to assign value and life opportunities in society that poses the greatest challenge to reducing racial/ethnic disparities. Furthermore, the intricate manner in which race/ethnicity and social status are interwoven and the resultant health implications on minority populations in the US present an additional set of unique challenges. We believe that the distinct set of challenges embedded in issues of race/ethnicity and social status and their impact on cancer prevention and risk, early detection and screening, and diagnosis and treatment ultimately delay progress toward the goal of reducing cancer health disparities in African-Americans and other racial/ethnic minority populations. This brief report will highlight specific conceptual challenges that impede progress toward the goal of reducing the racial/ethnic gap in cancer health disparities and present recommendations for future research and intervention.
Reducing Cancer Disparities Among Racial/Ethnic Minority Populations

Clarifying the Root Causes of Racial/Ethnic Cancer Disparities

The first task in addressing racial/ethnic cancer disparities requires that we better understand the root causes of inequities in disease among subpopulations and develop effective interventions and strategies to redress those inequities. However, the challenge lies in the complex, multifactorial nature of racial/ethnic disparities and our inability to point to a single etiological determinant of disease.

Why do African-Americans suffer disproportionately from cancer? Is it a function of biology and genetics, behavior, and lifestyle, or disadvantaged social class status? These are critical questions that will have to be addressed to reduce the racial/ethnic gap.

How do we define the biological and genetic contributions to health disparities in African-Americans and other racial/ethnic minority groups in relation to their disadvantaged social status and the accompanying low socioeconomic positioning and decreased access to quality care? Disentangling these multiple effects is a daunting task.

Defining the Contribution of Biology and Genetics

What role do biology and genetics play in health disparities among African-Americans? This is a key controversy framing the scientific debate on the root causes of racial/ethnic health disparities. There are those in the field who are committed to exploring the biological and genetic basis of health disparities and firmly believe that biology and genes play a central role in their root causes. The proponents of biology and genetics point to the examples of breast and prostate cancers. African-Americans diagnosed with breast and prostate cancers appear to experience disproportionately increased rates of high-grade and aggressive tumor profiles, and often present at relatively younger ages with more advanced-stage disease. These findings appear to point to some biological/genetic component, and thus research in this area of cancer etiology is ongoing. Still, there are those who believe that while biology and genetics may play a role, the biological and genetic factors are inextricably bound to environmental factors (e.g. gene–environmental interactions).

Defining the Contribution of Lifestyle and Behaviors

Clarifying the role of behavioral, lifestyle, and cultural factors and their impact on racial/ethnic cancer disparities is an important challenge. To date, we do not fully understand what effect the personal health behaviors of African-Americans have on pervasive and systemic population-based racial/ethnic disparities. The fact remains that regardless of their personal health practices, African-Americans are at greater risk for developing and dying from cancer and have the lowest survival times among all racial/ethnic groups after a cancer diagnosis. And while lifestyle behaviors such as diet, physical activity, smoking, and cancer screening may appear to be a personal choice on the surface, in reality they often have much deeper historical, economic, and political roots.

Take smoking, for example. According to the Surgeon General’s report “Tobacco Use Among US Racial and Ethnic Minority Groups,” tobacco use among minorities is attributed to a number of factors. These factors include socioeconomic status (SES), acculturation, stress, biological factors, limited English proficiency, the price of tobacco products, and targeted advertising within racial/ethnic minority communities. Strategies to effectively reduce population rates of tobacco use in these communities must therefore include culturally relevant approaches, resources for smoking cessation, policy changes, rigorous prevention research, and additional resources to build infrastructures to facilitate tobacco control within racial/ethnic minority communities.

Unfortunately, many African-American and Hispanic/Latino communities lack the necessary economic resources or political acumen to effectively mobilize against targeted tobacco campaigns in their communities. As a result, we have failed to see a substantial decline in tobacco use in minority populations, and consequently African-Americans experience higher lung cancer incidence and mortality rates and lower survival times compared with US Caucasians, due in part to their smoking behaviors. Hence, a seemingly personal decision to smoke tobacco is in reality rooted in wider social, economic, and political determinants of health and health disparities.

An example of the complexity of a seemingly personal health decision can also be seen in the case of cancer screening. Comparably high survival

---

Table 1: Cancer Incidence* and Mortality* by Race and Ethnicity, US 2001–2005

<table>
<thead>
<tr>
<th>Rank</th>
<th>African-American, Non-Hispanic</th>
<th>Hispanic(^{a, c})</th>
<th>Asian/Pacific Islander</th>
<th>American-Indian/Alaska Native</th>
<th>White, Non-Hispanic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Incidence</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Prostate (248.5)</td>
<td>Prostate (138.0)</td>
<td>Prostate (93.8)</td>
<td>Breast (female) (75.0)</td>
<td>Prostate (156.7)</td>
</tr>
<tr>
<td>2</td>
<td>Breast (female) (117.5)</td>
<td>Breast (female) (90.1)</td>
<td>Breast (female) (89.1)</td>
<td>Prostate (73.3)</td>
<td>Breast (female) (130.6)</td>
</tr>
<tr>
<td>3</td>
<td>Lung (76.0)</td>
<td>Colorectal (39.2)</td>
<td>Colorectal (40.9)</td>
<td>Lung (46.0)</td>
<td>Lung (65.1)</td>
</tr>
<tr>
<td>4</td>
<td>Colorectal (61.2)</td>
<td>Lung (33.3)</td>
<td>Lung (39.1)</td>
<td>Colorectal (43.5)</td>
<td>Colorectal (50.1)</td>
</tr>
<tr>
<td>5</td>
<td>Pancreas (15.9)</td>
<td>Pancreas (9.8)</td>
<td>Liver/hepatic (14.6)</td>
<td>Pancreas (8.5)</td>
<td>Pancreas (10.8)</td>
</tr>
<tr>
<td><strong>Mortality</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Lung (60.9)</td>
<td>Lung (23.2)</td>
<td>Lung (26.6)</td>
<td>Lung (40.9)</td>
<td>Lung (54.4)</td>
</tr>
<tr>
<td>2</td>
<td>Prostate (59.4)</td>
<td>Prostate (20.6)</td>
<td>Breast (female) (12.6)</td>
<td>Prostate (21.1)</td>
<td>Prostate (24.6)</td>
</tr>
<tr>
<td>3</td>
<td>Breast (female) (24.4)</td>
<td>Breast (female) (15.8)</td>
<td>Colorectal (12.0)</td>
<td>Breast (female) (17.1)</td>
<td>Breast (female) (24.4)</td>
</tr>
<tr>
<td>4</td>
<td>Colorectal (18.3)</td>
<td>Colorectal (13.3)</td>
<td>Prostate (11.0)</td>
<td>Colorectal (16.9)</td>
<td>Colorectal (18.3)</td>
</tr>
<tr>
<td>5</td>
<td>Pancreas (14.4)</td>
<td>Pancreas (8.3)</td>
<td>Liver/hepatic (10.9)</td>
<td>Pancreas (6.6)</td>
<td>Pancreas (10.2)</td>
</tr>
</tbody>
</table>

* Incidence data are from the 12 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, and Alaska Native); b. Mortality data from the National Center for Health Statistics (NCHS); c. Hispanic is not mutually exclusive from white, African-American, Asian/Pacific Islander, or American-Indian/Alaska Native.
rates exist for all racial/ethnic groups diagnosed at a localized stage. However, African-Americans are more likely to be diagnosed with late/advanced-stage cancers. The increased likelihood of a late/advanced-stage cancer diagnosis suggests that racial differences in survival could be reduced if more cancers in African-Americans were diagnosed and treated at a clinically localized stage. Several studies have concluded that a later stage at diagnosis is the primary reason for the higher likelihood of cancer mortality among African-Americans compared with US Caucasians. Thus, efforts to identify factors that increase the likelihood of early-stage diagnoses in African-Americans are ongoing.

However, the under-utilization of screening services among racial/ethnic minority populations is not simply a matter of personal choice. As with the example of tobacco smoking, low screening rates have been attributed to factors such as the lack of access to state-of-the-art cancer screening facilities, lack of provider recommendation for cancer screening, cultural and language barriers, and being uninsured or underinsured. Each of these factors is beyond the level of the individual and points to more complex social, political, and economic determinants of health and health disparities.

While individual-level factors such as biological and genetic endowment, lifestyle choices, and screening behaviors are challenges that will have to be addressed to ultimately reduce cancer disparities in African-Americans, individual factors do not fully explain the persistent inequalities in population-based cancer mortality rates. For example, individual factors alone cannot account for the increased mortality risk among African-Americans without a high-risk genetic profile who engage in healthy lifestyle behaviors (including cancer screening). Rather, population-based cancer mortality consistently traces along a class gradient whereby the most vulnerable and impoverished populations experience the highest cancer mortality, while the most privileged and affluent populations have the lowest.

### Defining the Role of Social Determinants

The sociopolitical and economic conditions of resource-poor communities have long been implicated in premature mortality in a number of disease outcomes, including cancer.

The critique of the targeting approach is that vulnerable to criticism because even the ‘best’ performing subgroups also fall short of key targets (based on HP2010 goals) to improve key cancer outcomes. The critique of the targeting approach is that we should be directing cancer prevention and control resources to improve the cancer risk profiles of all populations and that targeting only African-Americans is an inherently unfair strategy.

The counter-argument is that targeting specific high-risk racial/ethnic minorities is simply a matter of extending quality care interventions to disenfranchised populations who would not receive care at all or would routinely receive a different (often lower) quality standard of care than majority populations. Take the example of cancer clinical trials. The Selenium and Vitamin E Cancer Prevention Trial (SELECT) is the largest-ever prostate cancer prevention trial. Previous studies suggest that selenium and vitamin E (alone or in combination) may reduce the risk for developing...
prostate cancer by 60 and 30%, respectively, but only a large clinical trial such as SELECT could confirm those initial findings.20

The SELECT study began enrolling patients in August 2001. The recruitment of Caucasians to the clinical trial was rapidly outpacing that of African-Americans. The rapid recruitment of Caucasians in proportion to African-Americans persisted despite literature that cited African-American prostate cancer incidence rates being on average 60% higher than in Caucasian men.1

The inclusion criteria were broadened to enhance the recruitment of high-risk African-American men into this important cancer prevention clinical trial. Researchers also elected to reduce the minimum age eligibility from 55 to 50 years for African-American men because these men have a higher incidence of prostate cancer at a younger age compared with other groups. The SELECT eligibility criteria also allowed men with controlled comorbidities. Lowering the minimum age requirement to 50 years for all African-Americans resulted in the accrual of 1,723 men (33% of the total African-American accrual), which would not have been possible if the 55-year age limit (for Caucasians) had been a uniform requirement.29 When enrollment closed in June 2004, approximately 15% of the participants were African-American. This targeted strategy was effective not only for enhancing enrollment of an under-represented at-risk minority subpopulation, but also for improving the generalizability of the cancer clinical trial results.22

To effectively reduce the cancer disparity gap among African-Americans, the challenge will be to focus our efforts on how to equitably distribute resources in such a way as to improve the cancer outcomes of African-Americans without impeding the improvement of Caucasians and other racial/ethnic groups. Williams20 provides five principles for reducing the disparity gap among African-Americans: provide insurance coverage and access to high-quality care for all; provide a diverse healthcare workforce to ensure culturally competent care; deliver patient-centered care; maintain accurate and complete race/ethnicity data to monitor disparities in care; and set measurable goals for improving quality and ensure that goals are achieved equitably for all racial and ethnic minorities.

These individual-level principles can be implemented throughout the US healthcare system, by federal and state governments, health plans, hospitals, medical groups, and healthcare professionals.22 However, to aggressively reduce the cancer gap, individual-level principles will have to be implemented alongside societal-level principles that address the social, economic, and political determinants of racial/ethnic cancer disparities. Societal-level principles include providing universal healthcare that does not deliver unequal treatment based on race/ethnicity and SES; investing in education and job opportunities for racial/ethnic minorities; and improving residential and social environments.

Conclusion

Despite the advances in cancer detection and treatment, racial/ethnic minority populations continue to experience poorer cancer-related outcomes. This article has provided a brief discussion of the challenges of reducing and ultimately eliminating cancer disparities among African-Americans and other racial/ethnic populations. The conceptual challenges of disentangling the multiple factors that contribute to our understanding of the root causes of health disparities and issues surrounding targeting racial/ethnic minorities will have to be addressed to close the cancer gap.

22. LaVeist TA, Disentangling race and socioeconomic status: a key to understanding health inequalities, J Urban Health, 2005;82(Suppl. 3):xi–34.

US ONCOLOGY